ArticleJHLT open2026
A silver lining in the VAD sky? Impact of a silver dressing on left ventricular assist device-associated driveline infections.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Left ventricular assist devices (LVAD) constitute a mainstay of treatment for patients suffering from advanced heart failure. LVAD have been shown to significantly increase patient survival and quality of life. The therapy continues to be hampered by LVAD-specific complications that limit its wider appeal. Driveline infections (DLI) remain the Achilles' heel of LVAD therapy, with persistent rates of DLI plaguing many patients. Several studies have been carried out to evaluate the effectiveness of driveline dressing protocols, but there is no consensus on specific driveline management, and no prospective trial has ever been carried out. Methods: We conducted a single-center prospective randomized trial of a driveline dressing protocol to evaluate the safety and efficacy of a weekly silver patch-based driveline dressing kit. The Control group protocol included every 3 days changes with chlorhexidine cleansing, an occlusive dressing, and an anchoring device. The Silver group protocol included weekly dressing changes with chlorhexidine cleansing, a non-activated silver patch, an occlusive dressing, and an anchoring device. Twenty-three patients were enrolled in the study, with 11 in the control group and 12 in the silver group. The endpoints of the study were the occurrence of the first DLI, time to first DLI, and total number of DLI at 18 months. We used SAS to assess the significance of the primary endpoint. Results: At an average 18-month follow-up, the first DLI rate (0.061 vs 0.377 events per patient year [EPPY], Conclusion: A weekly driveline dressing protocol that includes a non-activated silver patch may provide protection against driveline infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.